Description

Dosage form

Flat round tablets with beveled edges from brown to dark brown interspersed.

On one side of the tablet is the word CIPLA", on the other - a fracture line.

Structure

Each tablet contains:

Leaf sennoside extract .... 93.33 mg (containing the sum of calcium salts of sennosides A and B in terms of sennoside B - 13.5 mg)

Excipients: lactose - 23.07 mg, starch - 43.56 mg, methyl parahydroxybenzoate - 0.04 mg, microcrystalline cellulose - 15.0 mg, talc - 11.13 mg, magnesium stearate - 0.93 mg, sodium lauryl sulfate - 0.93 mg, sodium carmellose 2.00 mg.

pharmachologic effect

Has a laxative effect, which occurs after 8-10 hours.

The laxative effect is due to the effect on the receptors of the large intestine, which enhances peristalsis.

Pharmacokinetics

In accordance with the International Convention (EMEAHMPWG11 / 99), when conducting clinical trials of herbal preparations, an isolated study of pharmacokinetic parameters is not required

Side effects

The laxative effect of the drug may be accompanied by colicky abdominal pain, flatulence.

With prolonged use, especially in high doses, water-electrolyte metabolism disorders, albuminuria, hematuria, melanin deposition in the intestinal mucosa, nausea, vomiting, diarrhea, urinary discoloration, skin rash, convulsions, vascular collapse, fatigue, confusion are possible.

Selling features

Available without a prescription

Special conditions

It is not recommended to use the drug for more than 2 weeks.

After taking the drug, urine may acquire a yellow-brown or red-lilac color.

Indications

constipation caused by hypotension and sluggish peristalsis of the large intestine

stool regulation for hemorrhoids, proctitis, anal fissures

Contraindications

Hypersensitivity to the components of the drug, spastic constipation, intestinal obstruction, abdominal pain of unknown origin, strangulated hernia, acute inflammatory diseases of the abdominal cavity, peritonitis, gastrointestinal and uterine bleeding, cystitis, disorders of water and electrolyte metabolism.

Drug interactions

With long-term use of SenadeВ® in high doses, it is possible to increase the action of cardiac glycosides and influence the action of antiarrhythmic drugs due to the possibility of hypokalemia.

With simultaneous use with thiazide diuretics, glucocorticoids, licorice root preparations, the risk of hypokalemia increases.

Dosage

It is taken internally, usually 1 time per day in the evening before bedtime, washed down with water or any drink.

Adults and children over 12 years old: 1 tablet per dose.

If there is no effect, the dose can be increased to 2-3 tablets.

Children 6-12 years old: 1/2 tablet and, if necessary, increase the dose to 1-2 tablets.

In the selection process, the same dose should be taken over several days and gradually increased by 1/2 tablet.

If, after reaching the maximum dose, there is no bowel movement within 3 days, a doctor should be consulted.

Overdose

diarrhea leading to dehydration

Name ENG

SENADE

Clinical and pharmacological group

Laxative drug that stimulates intestinal motility

ATX code

Senna glycosides

Dosage

1 tab.

- senna leaf extract 93.33 mg, containing the sum of calcium salts of sennosides A and B in terms of sennoside B 13.5 mg

Structure

Leaf sennoside extract. 93.33 mg (with the content of the sum of calcium salts of sennosides A and B in terms of sennoside B - 13.5 mg).

Excipients: lactose - 23.07 mg, starch - 43.56 mg, methyl parahydroxybenzoate - 0.04 mg, microcrystalline cellulose - 15.0 mg, talc - 11.13 mg, magnesium stearate - 0.93 mg, sodium lauryl sulfate - 0.93 mg, sodium carmellose 2.00 mg.

Indications

constipation caused by hypotension and sluggish peristalsis of the large intestine

stool regulation for hemorrhoids, proctitis, anal fissures.

INN / Active ingredient

sennosides A and B calcium salts (in terms of sennoside B)

Storage conditions and periods

The drug should be stored out of the reach of children, in a dry place at a temperature not exceeding 30 В° C.

The shelf life is 3 years.

Contraindications

spastic constipation

intestinal obstruction

abdominal pain of unknown origin

strangulated hernia

acute inflammatory diseases of the abdominal cavity

peritonitis

gastrointestinal and uterine bleeding

cystitis

violations of water and electrolyte metabolism

hypersensitivity to drug components.

It is prescribed with caution for liver and / or kidney diseases, during pregnancy, during breastfeeding, in conditions after abdominal operations.

Specifications